{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:07:31Z","timestamp":1773792451244,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-87553-z","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T09:02:11Z","timestamp":1737795731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study"],"prefix":"10.1038","volume":"15","author":[{"given":"Nargiz","family":"Majidova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hac\u0131","family":"Arak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faruk Recep","family":"Ozalp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"Bas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulhan Ozcelik","family":"Koker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erkan Buket","family":"Ozmarasal\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasemin Sagd\u0131c","family":"Karateke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teoman","family":"Sakalar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sendag","family":"Yaslikaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilknur Deliktas","family":"Onur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goncagul","family":"Akdag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Ogul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad","family":"Guliyev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebru Engin","family":"Delipoyraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okan","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurullah","family":"Ilhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozkan","family":"Alan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinem","family":"Akbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaprak","family":"Ca\u011flar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Kaan","family":"Guren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadiye","family":"Sever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halil Ibrahim","family":"Ellez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Selcukbiricik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Muhammed Atc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Bilici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nebi Serkan","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugba","family":"Basoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cengiz","family":"Karacin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail Oguz","family":"Kara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turkkan","family":"Evrensel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Dizdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif","family":"Atag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpaslan","family":"Ozgun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Kostek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"87553_CR1","doi-asserted-by":"crossref","unstructured":"Leonardi, G. et al. Cutaneous melanoma: from pathogenesis to therapy (review). Int. J. Oncol. ; (2018).","DOI":"10.3892\/ijo.2018.4287"},{"issue":"11","key":"87553_CR2","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis, L. E., Shalin, S. C. & Tackett, A. J. Current state of melanoma diagnosis and treatment. Cancer Biol. Ther. 20 (11), 1366\u20131379 (2019).","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"87553_CR3","first-page":"132","volume":"8","author":"OA Orzan","year":"2015","unstructured":"Orzan, O. A., \u0218andru, A. & Jecan, C. R. Controversies in the diagnosis and treatment of early cutaneous melanoma. J. Med. Life. 8 (2), 132\u2013141 (2015).","journal-title":"J. Med. Life"},{"issue":"19","key":"87553_CR4","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long, G. V. et al. Adjuvant dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma. N. Engl. J. Med. 377 (19), 1813\u20131823 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"87553_CR5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N. Engl. J. Med. 377 (19), 1824\u20131835 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"87553_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.det.2022.07.007","volume":"41","author":"J Lazaroff","year":"2023","unstructured":"Lazaroff, J. & Bolotin, D. Targeted therapy and immunotherapy in Melanoma. Dermatol. Clin. 41 (1), 65\u201377 (2023).","journal-title":"Dermatol. Clin."},{"issue":"2","key":"87553_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins, M. B. et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for patients with Advanced BRAF -Mutant Melanoma: the DREAMseq Trial\u2014ECOG-ACRIN EA6134. J. Clin. Oncol. 41 (2), 186\u2013197 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"87553_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto, P. A. et al. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for untreated BRAF -Mutated metastatic melanoma (SECOMBIT): a Randomized, Three-Arm, open-label phase II trial. J. Clin. Oncol. 41 (2), 212\u2013221 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"30","key":"87553_CR9","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/JCO.23.01136","volume":"41","author":"R Seth","year":"2023","unstructured":"Seth, R. et al. Systemic therapy for Melanoma: ASCO Guideline Update. J. Clin. Oncol. 41 (30), 4794\u20134820 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"87553_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","volume":"21","author":"R Dummer","year":"2020","unstructured":"Dummer, R. et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 21 (3), 358\u2013372 (2020).","journal-title":"Lancet Oncol."},{"issue":"17","key":"87553_CR11","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","volume":"29","author":"J Larkin","year":"2023","unstructured":"Larkin, J. et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III\/IV Melanoma: 5-Year efficacy and Biomarker results from CheckMate 238. Clin. Cancer Res. 29 (17), 3352\u20133361 (2023).","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"87553_CR12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/CAD.0000000000001120","volume":"32","author":"Q Shi","year":"2021","unstructured":"Shi, Q. et al. Interferon-\u03b11b for the treatment of metastatic melanoma: results of a retrospective study. Anticancer Drugs. 32 (10), 1105\u20131110 (2021).","journal-title":"Anticancer Drugs"},{"issue":"7","key":"87553_CR13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1634\/theoncologist.2014-0429","volume":"20","author":"NR Latimer","year":"2015","unstructured":"Latimer, N. R., Abrams, K. R., Amonkar, M. M., Stapelkamp, C. & Swann, R. S. Adjusting for the Confounding effects of Treatment switching\u2014the BREAK-3 trial: Dabrafenib Versus Dacarbazine. Oncologist 20 (7), 798\u2013805 (2015).","journal-title":"Oncologist"},{"issue":"11","key":"87553_CR14","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi, F. S. et al. Nivolumab plus Ipilimumab or Nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 19 (11), 1480\u20131492 (2018).","journal-title":"Lancet Oncol."},{"issue":"9","key":"87553_CR15","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert, C. et al. Pembrolizumab versus Ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20 (9), 1239\u20131251 (2019).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87553-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T09:02:14Z","timestamp":1737795734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87553-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["87553"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-87553-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Marmara University Ethics Committee approved the study (Approval Number 08.12.2023.1555)","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Informed consent was waived by (Marmara University Ethics Committee approved the study (Approval Number 08.12.2023.1555)) due to retrospective nature of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"3200"}}